ECO ANIMAL HEALTH GROUP PLC

Transaction in Own Shares • Oct 14, 2024

National Storage Mechanism | Additional information

RNS Number : 0749I

Eco Animal Health Group PLC

14 October 2024

14 October 2024

ECO Animal Health Group plc

("ECO" or the "Company")

EBT Share Purchase

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces it has been notified that the trustees of the ECO Animal Health Group EBT (the "EBT") have, on 11 October 2024 purchased 50,000 ordinary shares of 10p each in the Company ("Ordinary Shares") at a price of 72 pence per Ordinary Share.

These Ordinary Shares are to be held in the EBT and are intended to be used to satisfy the future vesting of share options granted to employees of the Company. The EBT is a discretionary trust for the benefit of the Company's employees, including the Directors of the Company. The purchase of Ordinary Shares by the EBT has been funded by a gift provided by the Company from its existing cash resources.

Following this transaction, a total of 50,000 Ordinary Shares are held by the EBT, representing approximately 0.07 per cent. of the Company's total voting rights.

-Ends-

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)	020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher	020 7496 3000
Investec (Joint Broker) Gary Clarence Lydia Zychowska	020 7597 5970
Equity Development Hannah Crowe Matt Evans	020 7065 2692
ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700 ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPGBWUUPCUBC